Marktanalyse - Colitis - Pipeline Review, H1 2017

Global Markets Direct
02.2017
94 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Colitis - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis — Pipeline Review, H1 2017, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Colitis - Overview

Colitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Colitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Colitis - Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Bristol-Myers Squibb Company

Concenter BioPharma Silkim Ltd

Cosmo Pharmaceuticals NV

CSA Biotechnologies LLC

Dr. Falk Pharma GmbH

EA Pharma Co Ltd

Genfit SA

Immuron Ltd

Innate Pharma SA

Ogeda SA

Peptinov SAS

Pfizer Inc

RDD Pharma Ltd

Saniona AB

Sigmoid Pharma Ltd

Soligenix Inc

Synovo GmbH

Colitis - Drug Profiles

AcTMP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKB-6899 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-346 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APY-0201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-1215 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSA-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSY-0073 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyloxalylglycine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elafibranor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ESN-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-124E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPH-33 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06425090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPV-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDD-2007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifamycin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-182 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Crohn's Disease and Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPC-1022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IL12 and IL23 for Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IL23 for Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Colitis - Dormant Projects

Colitis - Discontinued Products

Colitis - Product Development Milestones

Featured News & Press Releases

Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Colitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Colitis - Pipeline by Akebia Therapeutics Inc, H1 2017

Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2017

Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017

Colitis - Pipeline by Cosmo Pharmaceuticals NV, H1 2017

Colitis - Pipeline by CSA Biotechnologies LLC, H1 2017

Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2017

Colitis - Pipeline by EA Pharma Co Ltd, H1 2017

Colitis - Pipeline by Genfit SA, H1 2017

Colitis - Pipeline by Immuron Ltd, H1 2017

Colitis - Pipeline by Innate Pharma SA, H1 2017

Colitis - Pipeline by Ogeda SA, H1 2017

Colitis - Pipeline by Peptinov SAS, H1 2017

Colitis - Pipeline by Pfizer Inc, H1 2017

Colitis - Pipeline by RDD Pharma Ltd, H1 2017

Colitis - Pipeline by Saniona AB, H1 2017

Colitis - Pipeline by Sigmoid Pharma Ltd, H1 2017

Colitis - Pipeline by Soligenix Inc, H1 2017

Colitis - Pipeline by Synovo GmbH, H1 2017

Colitis - Dormant Projects, H1 2017

Colitis - Dormant Projects, H1 2017 (Contd..1), H1 2017

Colitis - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Colitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus